NCT01059084 is a NA clinical trial of Valacyclovir in HIV, sponsored by University of Washington.

Who is sponsoring NCT01059084?

NCT01059084 is sponsored by University of Washington.

What drugs are being tested in NCT01059084?

Interventions in NCT01059084: Valacyclovir.

What condition does NCT01059084 study?

NCT01059084 studies HIV, HIV Infections.

Is NCT01059084 still recruiting?

NCT01059084 is currently withdrawn. Last updated 4 December 2012.

Last reviewed 2012-12-04 · How we verify

NCT01059084

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons

Withdrawn NA Last updated 4 December 2012

What this trial tests

NA trial testing Valacyclovir in HIV. Withdrawn.

Timeline

1 January 2010

Primary endpoint
1 December 2012

1 December 2012

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Start date	1 January 2010
Primary completion	1 December 2012
Estimated completion	1 December 2012

Drugs / interventions tested

Valacyclovir — full drug profile →

Conditions studied

HIV — all drugs for HIV →
HIV Infections — all drugs for HIV Infections →

Sponsor

University of Washington

Who can join

18 and older, any sex, with HIV or HIV Infections. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To evaluate plasma HIV-1 levels after treatment with valacyclovir compared to baseline HIV-1 levels before treatment.
Time frame: Weeks (1-10)

Sponsor's own description

The purpose of this study is to look at the effect of daily herpes medication, valacyclovir, on HIV levels in the blood in persons who are HIV positive and do not have oral or genital herpes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.
Vanpouille C, Lisco A, Introini A, Grivel JC, et al · · 2012 · cited 17× · PMID 22314523 · DOI 10.1128/aac.05986-11

Verify or expand the search:

Other trials of Valacyclovir

Trials testing the same drug.

NCT06914479 — Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and · Phase 1 · recruiting
NCT07014397 — Effect of Valaciclovir on Inter-Appointment Pain in Endodontic Treatment of Necrotic Teeth · NA · completed
NCT05468619 — Neonatal Phase 1 Valacyclovir Study · Phase 1 · completed
NCT05536349 — Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chroni · Phase 2 · recruiting
NCT05492591 — A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster · Phase 2 · completed

Other recruiting trials for HIV

Currently open trials in the same condition.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01059084 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 4 December 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01059084.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing